OncLive recently published an article about a new treatment currently in clinical trials. Antibody drug conjugates (ADCs) work by targeting the cancer cell directly. Essentially, a toxic payload is attached to an antibody that seeks out a very specific molecule called Folate receptor alpha (FRa). This molecule is found in large numbers in ovarian epithelial cancers.
Immunotherapy, whether using a single or combination drug has had some mixed results and there are studies currently underway.
To read more about these newer treatment options and the clinical trials that are underway, follow this link.